Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer
Sponsor: Alliance for Clinical Trials in Oncology
A PHASE2 clinical study on Esophageal Cancer, this trial is completed. The trial is conducted by Alliance for Clinical Trials in Oncology and has accumulated 9 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
May 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Feb 2017 — May 2017 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Sep 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alliance for Clinical Trials in Oncology
- Bristol-Myers Squibb
- Eastern Cooperative Oncology Group
- National Cancer Institute (NCI)
- Pfizer
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Akron, United States, Allentown, United States, Ames, United States, Ann Arbor, United States, Anthony, United States, Aurora, United States, Baltimore, United States, Bangor, United States, Berlin Corners, United States, Bethlehem, United States and 144 more location s